Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZL-1310 vs Investigator's Choice in Relapsed Small Cell Lung Cancer
NCT07218146Phase 3Recruiting
- Sponsor
- Zai Lab
- Start
- Nov 2025
- Primary completion
- Jun 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 15
01
Overview
A Phase 3 trial of zocilurtatug pelitecan in small cell lung cancer (SCLC), sponsored by Zai Lab. Started Nov 2025; status: recruiting.
02
Drugs
zocilurtatug pelitecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07218146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07218146.